The Clinical Effectiveness and Safety of Intravesical Mitomycin-C and Gemcitabine Sequential Therapy

The aim of this study is to evaluate the effectiveness and safety of mitomycin-c and gemcitabine sequential instillation in BCG unresponsive high risk non-muscle invasive bladder cancer patients.

Trial Details

NCT ID
NCT06388720
Phase
PHASE2
Sponsor
National Cancer Center, Korea
Status
RECRUITING
Cancer Type
Bladder Cancer
Interventions
  • Mitomycin-C
  • gemcitabine
Locations (sample)
  • Goyang-si, South Korea|37.65639,126.835

Key Eligibility Criteria

  • a patient over the age of 20
  • Patients who are willing and able to complete a written test subject consent/approval for this examination.
  • Histologically confirmed high-risk NMIBC (according to AUA guidelines; High-grade T1 disease, any recurrent high-grade Ta, high-grade Ta \>3 cm, hi…
  • The most recent bladder examination/TURBT must be performed within 8 weeks before the initial administration of the trial treatment. Patients with …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Bladder Cancer Trials on Trialify →